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Abstract
Data on gastroenteropancreatic neuroendocrine neoplasms (NEN) G3 (well-
differentiated neuroendocrine tumors (NET G3) and neuroendocrine carcinoma
(NEC)) are limited. We retrospectively study patients with NET G3 and NEC
from eight European centers. Data examined included clinical and pathological
characteristics at diagnosis, therapies and outcomes. Two hundred and four
patients were analyzed (37 NET G3 and 167 NEC). Median age was 64 (21-89)
years. Tumor origin included pancreas (32%) and colon-rectum (27%). The
primary tumor was resected in 82 (40%) patients. Metastatic disease was evident
at diagnosis in 88% (liver metastases: 67%). Median Ki-67 index was 70% (30%
in NET G3 and 80% in NEC; P<0.001). Median overall survival (OS) for all patients
was 23 (95% CI: 18-28) months and significantly higher in NET G3 (99 vs 17
months in NEC; HR=8.3; P<0.001). Platinum-etoposide first line chemotherapy
was administered in 113 (68%) NEC and 12 (32%) NET G3 patients. Disease
control rate and ...
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Abstract
Data on gastroenteropancreatic neuroendocrine neoplasms (NEN) G3 (well-differentiated
neuroendocrine tumors (NET G3) and neuroendocrine carcinoma (NEC)) are limited.
We retrospectively study patients with NET G3 and NEC from eight European centers.
Data examined included clinical and pathological characteristics at diagnosis, therapies and
outcomes. Two hundred and four patients were analyzed (37 NET G3 and 167 NEC).
Median age was 64 (21–89) years. Tumor origin included pancreas (32%) and colon-rectum
(27%). The primary tumor was resected in 82 (40%) patients. Metastatic disease was evident at
diagnosis in 88% (liver metastases: 67%). Median Ki-67 index was 70% (30% in NET G3 and
80% in NEC; P!0.001). Median overall survival (OS) for all patients was 23 (95% CI: 18–28)
months and significantly higher in NET G3 (99 vs 17 months in NEC; HRZ8.3; P!0.001).
Platinum-etoposide first line chemotherapy was administered in 113 (68%) NEC and 12 (32%)
NET G3 patients. Disease control rate and progression free survival (PFS) were significantly
higher in NEC compared to NET G3 (P!0.05), whereas OS was significantly longer in NET G3
(PZ0.003). Second- and third-line therapies (mainly FOLFIRI and FOLFOX) were given in 79
and 39 of NEC patients; median PFS and OS were 3.0 and 7.6 months respectively after
second-line and 2.5 and 6.2 months after third-line chemotherapy. In conclusion, NET G3 and
NEC are characterized by significant differences in Ki-67 index and outcomes. While
platinum-based chemotherapy is effective in NEC, it seems to have limited value in NET G3.
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Gastroenteropancreatic neuroendocrine neoplasms (GEP-
NEN) are rare tumors defined by the presence of specific
biomarkers (Yao et al. 2008). The differentiation status is a
major prognostic factor, regardless of primary site and stage
(Lepage et al. 2004, Rindi et al. 2006, Yao et al. 2008).
Moreover, the European Neuroendocrine Tumor Society
(ENETS) developed a grading system (G1–G3) (Rindi et al.
2006), which has a strong prognostic value for survival
(Ferrone et al. 2007, Pape et al. 2008, Jann et al. 2011,
Panzuto et al. 2011, Khan et al. 2013). Grade 3 neoplasms
(defined as having a high proliferative index with a Ki-67
O20%) are highly heterogeneous, containing tumors that
are both well and poorly differentiated. The assumption
that all NEN G3 should be considered as a single entity
regarding diagnosis, prognosis and treatment has been
challenged. Sorbye et al. (2013) proposed separating NEN
G3 into two categories: those with a Ki-67 index ranging
from 20 to 55% and those with a Ki-67 index above 55%.
According to the current World Health Organization
(WHO) 2010 Classification, neuroendocrine carcinoma
(NEC) is defined by both a poorly differentiated
morphology (large-cell or small-cell type) and a prolifera-
tive activity defined by mitotic countO20/10 HPF and/or
Ki-67 indexO20% (Bosman et al. 2010). However, another
subgroup of NEN that are not included in the recent WHO
classification show a well-differentiated morphology,
although associated with a G3 grade (neuroendocrine
tumor (NET) G3) (Velayoudom-Cephise et al. 2013, Basturk
et al. 2014). Based on their data, Velayoudom-Cephise et al.
proposed a new classification for NEN G3 based on the
combination of morphology and grade.
Data on NEN G3 are limited and retrospective:
i) GEP-NEC accounts for w10–20% of all GEP-NEN
(Lepage et al. 2004, Yao et al. 2008); they have a
poor prognosis with a median survival of only 4–6
months in stage IV disease without treatment and up
to 6–19 months in patients receiving the standard
first-line, platinum-etoposide chemotherapy. In the
course of the disease, almost all NEC show resistance
to first-line chemotherapy. However, second-line
treatment is not codified (Moertel et al. 1991, Mitry
et al. 1999, Fjallskog et al. 2001, Janson et al. 2010,
Strosberg et al. 2010, Oberg et al. 2012). The types and
benefits of second-line therapeutic regimens still have
to be evaluated.
ii) Data on GEP-NET G3 are even more limited; they
account forw10%ofG3-GEP-NEN (Scoazec etal. 2012).
NET G3 appear to have a significantly more protracted
clinical course than NEC. First-line therapy is not
codified. It might be expected that they benefit from
less aggressive chemotherapeutic regimens routinely
used in NET G2 (e.g., temozolomide-based therapy).
The aim of this study was to describe characteristics,
prognosis and response to treatment of GEP-NEN G3,
comparing NET G3 (defined, as above: well-differentiated
NET with a G3 grading) and NEC (Table 1). For this
purpose, we performed a retrospective analysis of a cohort
of 204 patients with GEP-NEN G3, from eight European
centers.
Patients and methods
Patients were identified from hospital chart codings and
hospital databases. The inclusion criteria were: i) initial
diagnosis of NEN G3 from January 2000 to December
2013, ii) histopathologically confirmed diagnosis by
synaptophysin (Syn) and/or chromogranin A (CgA)
positivity, iii) GEP primary or of unknown primary and
iv) Ki-67 index O20% or poorly differentiated
morphology. Mixed tumors (MANEC) and NEN G3 with-
out morphological differentiation available were
excluded. Regarding quality of the pathology data, all
the centers involved are tertiary hospitals that have expert
pathologists in NET reviewing the samples before multi-
disciplinary meetings.
Data captured included demographics (name of NET
center, age at diagnosis, gender, date of diagnosis); clinical
Table 1 Neuroendocrine neoplasm Grade 3 (NEN G3) represents two groups regarding the morphology and the grading:
neuroendocrine carcinoma (NEC) and neuroendocrine tumor Grade 3 (NET G3)
Neuroendocrine neoplasm Morphology (differentiation) Grading G1-G3 (Ki-67 index in %) Abbreviation
Neuroendocrine tumor Grade 1 Well-differentiated G1 (%2%) NET G1
Neuroendocrine tumor Grade 2 Well-differentiated G2 (3–20%) NET G2
Neuroendocrine tumor Grade 3 Well-differentiated G3 (O20%) NET G3
Neuroendocrine carcinoma Poorly-differentiated (large or small cell) G3 (O20%) NEC
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(conventional imaging, fludeoxyglucose (18F), positron
emission tomography (FDG-PET), somatostatin receptor
imaging); pathology (origin and type of tissue specimen,
TNM stage (ENETS), Ki-67 index/mitotic count, differen-
tiation, cell size, immunohistochemistry (CgA, Syn));
treatment (surgical intervention, first-, second- and
third-line chemotherapy) and follow-up. Response to
chemotherapy was analyzed according to the following
criteria: type of regimen, start and end date of chemother-
apy, best response (local radiological review), progression
free survival (PFS) and overall survival (OS).
Statistical analysis
Categorical variables were expressed as percentages and
compared by the c2-test or with Fisher’s exact test, as
appropriate. Continuous variables were expressed as
medians with the range. PFS was calculated from the
initiation of chemotherapy to the date of disease
progression, according to local radiologic assessment or
death from any cause, whichever occurred first. OS was
calculated from the initiation of each chemotherapy line
to the date of death or last follow-up. PFS and OS were
assessed using Kaplan–Meier analysis and comparisons
were performed using the log-rank test. A P value of!0.05
was considered statistically significant. Cox proportional
Table 2 Patient and tumor characteristics
Characteristics All cases NET G3 NEC P
Number, n (%) 204 (100) 37 (18) 167 (79)
Age, median (range), years 63 (21–89) 52 (22–78) 64 (21–89) 0.001
Male, n (%) 122 (60) 20 (54) 102 (61) 0.46
Functional tumours, n (%) 9 (4) 5 (14) 4 (2) 0.003
Primary tumour location, n (%) 0.001
Pancreas 65 (32) 24 (65) 41 (25)
Colon 31 (15) 0 (0) 31 (19)
CUP 28 (14) 3 (8) 25 (15)
Rectum 24 (12) 3 (8) 21 (13)
Stomach 17 (8) 3 (8) 14 (8)
Other 13 (6) 1 (3) 12 (7)
Small bowel 11 (5) 2 (5) 9 (5)
Esophagus 8 (4) 0 (0) 8 (5)
Duodenum 7 (3) 1 (3) 6 (4)
Stage, n (%) 0.41
I–II 15 (7) 4 (11) 11 (7)
III 44 (22) 10 (27) 34 (20)
IV 145 (71) 23 (62) 122 (73)
Number of metastatic sites, n (%) 0.46
0 25 (12) 5 (14) 20 (13)
1 79 (41) 18 (49) 61 (39)
O1 91 (44) 14 (38) 77 (49)
Metastatic sites, n (%)
Liver 137 (67) 29 (78) 108 (65) 0.14
Peritoneal 33 (16) 5 (14) 28 (17) 0.24
Lung 19 (9) 2 (5) 17 (10) 0.14
Brain 5 (3) 0 (0) 5 (3) 0.24
Bone 25 (12) 7 (19) 18 (11) 0.13
Lymphatic 81 (40) 14 (38) 67 (40) 0.54
Other 22 (10) 4 (11) 18 (11) 0.27
Positive FDG-PET, n (%) 65/76 (86) 9/12 (75) 56/64 (88) 0.47
Positive SRS, n (%) 44/82 (54) 21/24 (92) 23/58 (40) !0.001
Synaptophysin C, n (%) 184/192 (96) 33/34 (97) 151/158 (96) 0.81
Chromogranin AC, n (%) 147/189 (78) 32/35 (91) 115/154 (75) 0.08
Cell size for NEC, n (%)
Small cell – 55/128 (43)
Large cell – 73/128 (57)
Ki-67 index, median (range) 70 (21–100) 30 (21–70) 80 (25–100) !0.001
Surgery of primary tumour, n (%) 82 (40) 22 (60) 60 (36) 0.01
NET, neuroendocrine tumour; NEC, neuroendocrine carcinoma; SRS, somatostatin receptor imaging; CUP, carcinoma of unknown primary.
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parameter with OS. For continuous variables, the cut-off
level chosen was their median value; furthermore, only
variables with a P value of !0.10 at univariate analysis
were introduced in the Cox model. Relative risks were
expressed as hazard ratios (HRs) with 95% CIs. The cut-off
date for follow-up was July 1, 2014. All statistical analyses
were performed using the Statistical Package for Social
Sciences, version 20.0 (Chicago, IL, USA).
Results
Patient characteristics
Overall, 233 patients were included from eight tertiary
centers. Twenty-nine (12%) patients were excluded due to
violation of inclusion/exclusion criteria. Characteristics of
the remaining 204 patients included in this multi-centric
retrospective study are summarized in Table 2. The
majority of the patients (nZ136, 67%) were initially
diagnosed from the beginning of 2010 onwards. The
median time of follow-up of those patients alive was 14.5
(range 1.1–124.7) months. Patients were significantly
younger in the NET G3 cohort (PZ0.001) and were
significantly more likely to have a functional tumor
compared to NEC (PZ0.003) (Table 2). Primary local-
ization was more often in the pancreas (65%) for NET G3,
while colorectal NEC was more common than colorectal
NET G3 (Table 2). Nuclear medicine imaging did not
identify a significant difference in FDG-PET uptake
between both cohorts, but SRS uptake was more frequent
and higher in NET G3 tumors.
Histopathology
Thirty-seven (18%) and 167 (79%) cases showed well
differentiated or poorly differentiated morphological
features respectively, defining them as NET G3 and NEC.
The median Ki-67 value across all tumors was 70% (range
21–100), with the distribution of Ki-67 values in relation to
differentiation displayed in Fig. 1. Median Ki-67 in the NEC
group (80%, range: 25–100) was significantly higher than
in NET G3 (30%, range: 21–70; P!0.001). In those cases
with Ki-67 O55%, almost all tumors were poorly differ-
entiated, whereas the subgroup with a Ki-67 index of
between 21 and 55% were very heterogeneous in terms of
differentiation (Fig. 1). A subgroup of NEC patients had the
morphological description assessed according to the WHO
2010 definition; 55 (43%) had small-cell and 73 (57%) had
large-cell carcinoma. The Ki-67 index was significantly
higher in small-cell NEC vs large-cell NEC (80% vs 70%;
PZ0.025). CgA and Syn staining were not significantly
different between NET G3 and NEC, although NEC seemed
to show less CgA staining (75% vs 91%, PZ0.08).
Survival
Over the study period, death was recorded in 110 of the
patients (54%). Median OS across all of the patients was 22.8
(95% CI: 17.8–27.9) months (Fig. 2a) and was significantly
higher (HRZ8.3 (95% CI: 2.9–23.81); P!0.001) in NET G3
(median 98.7 months, 95% CI: 53.9–143.5) than in NEC
(median 17 months, 95% CI 13.5–20.5) (Fig. 2b) after
multivariate analysis. Results of univariate analysis and cox
regression on other prognostic factors for survival are
summarized in Table 3. TNM staging proved to be of
prognostic relevance (Fig. 2c), with statistical significance
according to both univariate and multivariate analysis.
Ki-67 O55% was associated with worse survival at
univariate analysis, but not at multivariate analysis.
Treatment
Twelve (32%) patients with NET G3 and 113 (68%)
patients with NEC were treated by a platinum-etoposide
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Figure 1
Ki-67 distribution according to differentiation in Grade 3 neuroendocrine
neoplasms.
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first-line chemotherapy, 1.0 (0–71.5) months after the
diagnosis. In this platinum-treated population, disease
control rate (DCR) (33% vs 68%; PZ0.03) and median PFS
(2.4 vs 5.0 months; PZ0.049) were significantly lower in
NET G3 compared to NEC respectively, while median OS
remained significantly longer in NET G3 than in NEC
patients (PZ0.003) (Table 4). Among NEC patients, DCR
was 31/40 (77%) in small-cell vs 32/53 (60%) in large-cell
NEC (PZ0.08); DCR was 33/52 (63%) in pancreatic and
21/33 (64%) in colorectal primaries (PZ0.82). The other
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Figure 2
Survival in patients with Grade 3 neuroendocrine neoplasm, in the whole population (a) and according to differentiation (b), and TNM stage (c) after
multivariate analysis.
Table 3 Univariate analysis and Cox regression on prognostic baseline factors for survival in patients with G3 neuroendocrine
neoplasms
Characteristics
Univariate analysis Multivariate analysis Cox regression
P value HR (95% CI) P value
Age, % vs Omedian of 63 years 0.57
Gender, male vs female 0.65
Primary location
CUP vs other 0.04 0.46 (0.21–1) 0.052
Duodeno-pancreatic vs other 0.06 0.61 (0.32–1.16) 0.13
Colorectal vs other 0.07 0.52 (0.27–1) 0.051
Esophagus-stomach vs other 0.36
Functionality, yes vs no 0.057 1.42 (0.38–5.36) 0.6
TNM-staging !0.001
Stage IV vs ICII 0.16 (0.04–0.61) 0.007
Stage IV vs III 0.48 (0.21–0.98) 0.045
Number of metastatic sites !0.001
0 vs 1 1.5 (0.37–6.13) 0.58
0 vs O1 2.18 (0.45–10.54) 0.33
Type of metastatic sites
Liver metastases, yes vs no 0.02 0.7 (0.35–1.41) 0.32
Peritoneal metastases, yes vs no 0.009 0.79 (0.43–1.45) 0.45
Lung metastases, yes vs no 0.02 0.58 (0.27–1.25) 0.16
Bone metastases, yes vs no 0.5
Lymphatic metastases, yes vs no 0.045 1.2 (0.69–2.1) 0.51
Brain metastases, yes vs no 0.7
Other metastases, yes vs no 0.18
FDG-PEG positivity, yes vs no 0.15
SRS positivity, yes vs no 0.23
NET G3 vs NEC !0.001 8.3 (2.9–23.81) !0.001
Large vs small cell NEC 0.87
Synaptophysin positivity, yes vs no 0.39
Chromogranin A positivity, yes vs no 0.51
Ki-67, %50% vs O50% !0.001 1.26 (0.73–2.17) 0.41
HR, hazard ratio; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; SRS, somatostatin receptor imaging; CUP, carcinoma of unknown primary.
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treatments used in NET G3 were very heterogeneous and
could not be compared with platinum-etoposide in this
retrospective study. With regard to the subgroup of
patients with NEC, 79 patients (48%) and 39 patients
(23%) received second- and third-line chemotherapy,
mainly irinotecan with fluorouracil and folinic acid
(FOLFIRI), oxaliplatin with fluorouracil and folinic acid/
capecitabine (FOLFOX/Capox), or temozolomide-based
chemotherapy. Efficacy of second- and third-line
chemotherapy are displayed in Table 5; median PFS was
w3 months and 2.5 months respectively.
Discussion
With regard to the current WHO classification (2010),
NEC is considered both, a tumor that is defined by its high
proliferative activity and also by its poorly differentiated
tumor morphology. Morphology has played an important
role in defining tumors in the past, but now this parameter
may be being neglected within routine care, as the
definition of NEC is often given by just providing its
grade. This is reflected by the most recent publications of
NEN G3, where tumor morphology is not even mentioned
(Welin et al. 2011, Sorbye et al. 2013). While most NEN
G3 are of poorly differentiated morphology, there is a
subgroup of well-differentiated NET with G3 grading that
is not reflected by the latest WHO classification. Further-
more, although Ki-67 is key to the grading system adopted
by WHO, we show that morphology was found to be more
informative than the Ki-67 index to stratify NEN G3
patients outcomes. Usually, NET G3 have a consistently
lower Ki-67 index compared to NEC, ranging between
20 and 50%.
Several studies have challenged the assumption that
NET G3 and NEC are overlapping entities. It has been
suggested that these two cancers differ in terms of
prognosis, SRS uptake and response to chemotherapy
regimens (Vilar et al. 2007, Velayoudom-Cephise et al.
2013). The response to first-line platinum-etoposide
represents one of the most relevant disparities.
Velayoudom-Cephise et al. (2013) reported 0% objective
response in NET G3 patients vs 31% in large-cell NEC
patients. This was in agreement with the results of the
NORDIC study, which compared subgroups with
Ki-67 !55% vs O55%, recording objective response rates
of 15% vs 42% respectively (Sorbye et al. 2013). In our
study, the response rates to platinum-etoposide were
similar to those reported in the above-mentioned studies
(39% vs 2% for NEC and NET G3 respectively), underlining
the fact that differentiation is key when considering the
sensitivity to the standard first-line chemotherapy. We
hypothesize that NET G3 could have been enrolled in
Sorbye’s study, explaining the lower response rate to
platinum-etoposide within the group of tumors with a
Ki-67!55, particularly from pancreas localization. Among
our NEC patients, we reported similar responses between
duodeno-pancreatic and colorectal primaries. A trend
exists of better response to platinum-etoposide in small-
cell vs large-cell NEC. Limited data and no guidelines are
currently available for managing patients with NET G3. The
observation that most experts feel these cases to be different
from NEC is supported by their first choice to use
Table 4 Efficacy of platinum-etoposide first-line chemo-
therapy according to differentiation of Grade 3 neuroendocrine
neoplasms
NET G3 NEC P
Number of patients 12 113
OR, n (%) 2 (17) 39 (35) 0.18
SD, n (%) 1 (8) 25 (22) 0.24
PD, n (%) 6 (50) 30 (27) 0.09
NA, n (%) 3 (25) 19 (17) 0.36
DCR (%) 3 (33%) 64 (68%) 0.036
Median PFS (95% CI),
months
2.4 (1.1–3.8) 5.0 (4.0–6.1) 0.049
Median OS (95% CI),
months
NR 16.4 (13.4–19.5) 0.003
OR, objective response; SD, stable disease; PD, progressive disease; NA, not
available; DCR, disease control rate; PFS, progression free survival;
OS, overall survival; NR, not reached.
Table 5 Type and efficacy of second-line and third-line
chemotherapies in poorly differentiated NEC
Second-line Third-line
Number of patients (%) 79 (48%) 39 (23%)
Type of regimen, n (%)
FOLFIRI 30 (38) 11 (28)
FOLFOX/Capox 14 (18) 7 (18)
Platinum/etoposide 12 (15) 3 (8)
Temozolomide-based 7 (9) 4 (10)
Clinical trials testing
sunitinib
3 (4) 1 (3)
Othera 13 (16) 13 (33)
Objective response, n (%) 12 (16) 4 (10)
Stable disease, n (%) 15 (20) 3 (8)
Progressive disease, n (%) 38 (50) 19 (49)
Not available, n (%) 12 (16) 13 (33)
Median progression free
survival (95% CI) in months
2.98 (2.56–3.41) 2.53 (1.38–3.67)
Median overall survival
(95% CI) in months
7.64 (6.42–8.86) 6.2 (3.78–8.62)
aGemcitabine, docetaxel/cisplatin/5-FU, dacarbazine-based, etoposide.
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centers, alternative treatment modalities, such as temozo-
lomide/capecitabine and FOLFOX, routinely used in NET
G2, are the preferred choice over platinum/etoposide
chemotherapy for NET G3.
Another unanswered issue is the selection of therapy
after the failure of a platinum-based regimen in NEC;
second-line treatments are not yet established. Alternative
regimens include temozolomide combinations, FOLFIRI,
FOLFOX and topotecan (Welin et al. 2011, Hentic et al.
2012, Olsen et al. 2012, Olsen et al. 2014, Hadoux et al.
2015). Published trials have included very hetero-
geneous populations, which make direct comparisons
impossible. In particular, a retrospective study of temozo-
lomide G capecitabine G bevacizumab in 25 patients
included mainly patients with a Ki-67 between 20 and
30%; it reported an objective response rate of 32%
(Welin et al. 2011). However, it is difficult to recommend
temozolomide as an optional treatment for all NEN G3
based on this analysis, or for all NET G3 irrespective of
their primary tumor site. Furthermore, the morphological
feature was not a variable considered in this particular
report. On the contrary, a study reported the efficacy
of FOLFIRI as second-line therapy in a NEC population
with a median Ki-67 of 50%, excluding NET G3
(Hentic et al. 2012). Similar results were obtained by
Hadoux et al. (2015) using FOLFOX in a similar popu-
lation. A retrospective study, using topotecan in 22
patients with clearly poorly differentiated tumors with a
median Ki-67 of 95%, showed no convincing anti-tumor
activity (Olsen et al. 2014).
Our study presents one of the largest well-charac-
terized cohorts of NEN G3. We analyzed these data with
the aim of generating hypotheses to drive further clinical
trials. In this respect, retrospective series are key to
generating new approaches in this rare disease in which
it is difficult to conduct randomized trials. Retrospective
collection of data has common well-known biases, such as
the detection bias (the data collected are those from the
longest survivors). Another potential weakness of this
study was the lack of blinded centralized pathology review
to ensure perfect accuracy regarding classification of
morphology; however, all centers were expert NET groups
with recognized and experienced pathologists in this field.
In addition, all the centers recruiting patients were tertiary
hospitals, which might have affected the patient survival
and the chemotherapy schedules applied.
In conclusion, in our study, differentiation was the
strongest independent factor for OS. Grade 3 NEN
represent a heterogeneous disease that makes clinical
decisions extremely difficult. Strikingly, platinum-based
chemotherapy was not the first choice of treatment for
NET G3 and seemed significantly less effective in NET G3
compared to NEC. This latter fact shows that within the
NET expert community NET G3 and NEC are considered
clearly a different entity. Finally, our study presents
interesting data on the efficacy of second- and third-line
treatment of NEC, which could be useful in designing new
prospective studies.
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